Attending Physician; Hematology, Oncology and Blood and Marrow Transplantation
Assistant Professor of Clinical Pediatrics, Keck School of Medicine of USC
  • Summary
  • Publications
  • Research
  • Locations

After completing his residency and fellowship at Children’s Hospital Los Angeles, Dr. Robison completed an additional fellowship in Pediatric Neuro-Oncology at the Dana-Farber / Children’s Hospital Cancer Center in Boston. He served as clinical instructor at Harvard Medical School and attending staff in the Pediatric Neuro-Oncology Program at Dana Farber Cancer Institute and Boston Children’s Hospital from 2010 to 2013.

In April 2013 he joined the faculty of the University of Southern California Keck School of Medicine as assistant professor of pediatrics, and now serves as attending staff in the Pediatric Neuro-Oncology Program at Children's Hospital Los Angeles.

Clinical Interests

Treatment of children and adolescents with brain and spinal cord tumors

Education

Medical School: 

University of Southern California Keck School of Medicine

Internship: 

Children's Hospital Los Angeles, Pediatrics

Residency: 

Children's Hospital Los Angeles, Pediatrics

Fellowship: 

Children's Hospital Los Angeles, Pediatric Hematology/Oncology; Boston Childrens Hospital, Pediatric Neuro-Oncology

Accomplishments

Certification: 

Pediatrics and Pediatric Hematology/Oncology, American Board of Pediatrics

Publications: 

Robison NJ, Campigotto F, Chi SN, Manley PE, Turner CD, Zimmerman MA, Chordas CA, Werger AM, Allen JC, Goldman S, Rubin JB, Isakoff MS, Pan WJ, Khatib ZA, Comito MA, Bendel AE, Pietrantonio JB, Kondrat L, Hubbs SM, Neuberg DS, Kieran MW. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatric Blood and Cancer, 2013 Oct 4 [Epub ahead of print].

Liu D, Song L, Brawley VS, Robison N, Wei J, Gao X, Tian G, Margal A, Ahmed NM, Asgharzaedh S, Metelitsa LS. Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clin Immunol 2013

149: 55.

Liu D, Song L, Brawley VS, Robison N, Wei J, Gao X, Tian G, Margal A, Ahmed NM, Asgharzaedh S, Metelitsa LS. Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clin Immunol 2013

149: 3. Erdreich-Epstein A, Robison N, Ren X, Zhou H, Xu J, Davidson TB, Schur M, Gilles FH, Ji L, Malvar J, Shackleford GM, Margol A, Krieger MD, Judkins AR, Jones DT, Pfister SM, Kool M, Sposto R, Asgharzadeh S. PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas. Clin Cancer Res. 2013 Dec 3 [Epub ahead of print].

Robison NJ, Prabhu S, Sun P, Chi SN, Kieran MW, Manley P, Cohen LE, Goumnerova L, Smith E, Scott M, London W, Ullrich NJ. Predictors of neoplastic disease in children with isolated pituitary stalk thickening. Pediatric Blood and Cancer 2013

60: 1630.

Bandopadhayay P, Bergthold G, London WB, Goumerova LC, Morales La Madrid A, Marcus KJ, Guo D, Ullrich NJ, Robison NJ, Chi SN, Beroukhim R, Kieran MW, Manley P. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatric Blood and Cancer, In Press.

Research Interests: 
  • Pediatric brain tumors
  • Tumor microenvironment
  • Antiangiogenic and immunomodulatory treatment strategies
  • Treatment of diffuse pontine giloma and low-grade glioma
  • Neurofibromatosis

Dr. Robison is interested in developing clinical trials that test new strategies in the treatment of children with brain tumors. His specific areas of interest are novel treatments targeting the tumor microenvironment, including antiangiogenic and immunomodulatory strategies; overcoming treatment resistance; treatment of diffuse pontine glioma and other poor prognosis brain tumors; treatment of low-grade glioma; neurofibromatosis.

4650 Sunset Blvd.
MS #54
Los Angeles, CA 90027
Phone: 323-361-4624Office
Fax: 323-361-7128Fax